The use of agonistic anti-CD40 therapy in treatments for cancer
Access Status
Authors
Date
2012Type
Metadata
Show full item recordCitation
Source Title
Additional URLs
ISSN
School
Collection
Abstract
Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to itsaction on both immuneand tumor cells. It has the ability to “precondition” dendritic cells, allowingthem to prime effective cytotoxic T-cell responses. Thus, anti-CD40 antibody provides an idealtherapy for combination with traditional cancer treatments (i.e., chemotherapy, surgery) in orderto elicit immune-mediated anti-tumor effects. This review summarizes the mechanisms of actionof agonistic anti-CD40, the use of mouse models to investigate its effects and combinations withother therapies in vivo, and current clinical trials combining humanized anti-CD40 antibody withchemotherapy and/or other immunotherapies.
Related items
Showing items related by title, author, creator and subject.
-
Jackaman, Connie; Nelson, Delia (2012)Targeting interleukin-2 (IL-2) and/or agonist anti-CD40 antibody (Ab) into tumors represents an effective vaccination strategy that avoids systemic toxicity and resolves treated-site tumors. Here, we examined IL-2 and/or ...
-
Jackaman, Connie; Radley-Crabb, Hannah; Soffe, Z.; Shavlakadze, T.; Grounds, M.; Nelson, Delia (2013)Changes to innate cells, such as macrophages and myeloid-derived suppressor cells (MDSCs), during aging in healthy or tumor-bearing hosts are not well understood. We compared macrophage subpopulations and MDSCs from healthy ...
-
Jackaman, Connie; Yeoh, T.; Acuil, M.; Gardner, Joanne; Nelson, Delia (2016)© 2016 Taylor & Francis Group, LLC.We used a murine model to monitor changes to myeloid cell subsets, i.e., myeloid-derived suppressor cells (MDSCs), M1 macrophages that secrete pro-inflammatory cytokines and express CD40 ...